Alterations of striatal glutamate transmission in rotenone-treated mice: MRI/MRS in vivo studies.
Animal models treated with agricultural chemicals, such as rotenone, reproduce several degenerative features of human central nervous system (CNS) diseases. Glutamate is the most abundant excitatory amino acid transmitter in the mammalian central nervous system and its transmission is implicated in a variety of brain functions including mental behavior and memory. Dysfunction of glutamate neurotransmission in the CNS has been associated with a number of human neurodegenerative diseases, either as a primary or as a secondary factor in the excitotoxic events leading to neuronal death. Since many human CNS disorders do not arise spontaneously in animals, characteristic functional changes have to be mimicked by toxic agents. Candidate environmental toxins bearing any direct or indirect effects on the pathogenesis of human disease are particularly useful. The present longitudinal Magnetic Resonance Imaging (MRI) studies show, for the first time, significant variations in the properties of brain ventricles in a rotenone-treated (2 mg/kg) mouse model over a period of 4 weeks following 3 days of rotenone treatment. Histopathological analysis reveals death of stria terminalis neurons following this short period of rotenone treatment. Furthermore, in vivo voxel localized (1)H MR spectroscopy also shows for the first time significant bio-energetic and metabolic changes as well as temporal alterations in the levels of glutamate in the degenerating striatal region. These studies provide novel insights on the effects of environmental toxins on glutamate and other amino acid neurotransmitters in human neurodegenerative diseases.
Moussa
Charbel E-H
CE
Laboratory of Molecular Neurochemistry, Department of Biochemistry, Molecular and Cell Biology, Georgetown University Medical Center, Washington, DC 20007, USA. cem46@georgetown.edu
Rusnak
Milan
M
Hailu
Ayichew
A
Sidhu
Anita
A
Fricke
Stanley T
ST
D000818:Animals; D001921:Brain / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D002952:Citric Acid Cycle / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D005246:Feedback / Q000502:physiology; D018698:Glutamic Acid / Q000502:physiology*; D007150:Immunohistochemistry; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D017072:Neostriatum / Q000378:metabolism / Q000503:physiopathology*; D020258:Neurotoxicity Syndromes / Q000503:physiopathology*; D010085:Oxidative Phosphorylation / Q000187:drug effects; D012402:Rotenone / Q000633:toxicity*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D014475:Uncoupling Agents / Q000633:toxicity*
D014475:Uncoupling Agents; D012402:Rotenone; D018698:Glutamic Acid; D014446:Tyrosine 3-Monooxygenase